09 June 2000
Post-TransplanIt Immune Serological Markers May Be Predictive of Chronic Rejection
Ronald H KermanAnn Transplant 2000; 5(2): 24-28 :: ID: 497522
Abstract
Chronic rejection isan important cause ofgraft dysfunction and loss after the first posttransplant year [1].Two working hypotheses have evolved to explainthe etiology of the process. The first is an antigen-dependent phenomenon influenced by early immunological injury whereas the second is related to alloantigen-independent events contributing to progressive chronic graft dysfunction [2,3]. Our study, reported herein, focuses on the antigen-dependent aspects of chronic rejection. Several hypotheses have been proposed to explain the immunologic basis of chronic rejection. The first involvesrecurrent episodes of acute rejection that lead to protracted tissue damage and scarring [2,3].An alternative immune hypothesis to explain chronic rejection is that the immune-regulatory mechanisms that prevent acute rejection playa role in chronic rejection by supporting B cell responses and antibody formation. Therefore, chronic rejection may be a predominantly antibody- mediated form of graft damage..
Keywords: post-transplant antibody, chronic rejection
In Press
Original article
Learning Curve and Outcomes of Pure Laparoscopic Donor Major Hepatectomy Performed by Fellowship-Trained Su...Ann Transplant In Press; DOI: 10.12659/AOT.953061
Original article
Role of Psychological Resilience on Emotional Health in Kidney and Liver Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.952824
Original article
Analysis of Factors Influencing the Psychological State of Patients After Autologous Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.953645
Original article
Fundamental Strategies and Technical Perspectives in Bile Duct Anastomosis for Living Donor Liver Transplan...Ann Transplant In Press; DOI: 10.12659/AOT.953761
Most Viewed Current Articles
24 Aug 2021 : Review article 21,725
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 17,946
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
22 Nov 2022 : Original article 16,696
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
05 Apr 2022 : Original article 16,590
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604






